Company name not provided — a pre-revenue company that reported no revenue in 2024 or 2025 and incurred net losses of $58,200,000 in 2025 and $65,363,000 in 2024; total assets were $157,059,000 and total stockholders' equity was $98,654,000 as of 2025.

I can rewrite this summary for you. Please provide the company's name to use as the title, and I’ll produce the Markdown-formatted version.

Boundless Bio, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics targeting extrachromosomal DNA for cancer treatment.

# Boundless Bio, Inc. Overview

**Company Profile:**
- **Name:** Boundless Bio, Inc.
- **Incorporation:** Delaware
- **Founded:** 2018
- **Address:** 10955 Alexandria Way, Suite 100, San Diego, CA, 92121
- **Contact:** (858) 766-9912
- **Trading Symbol:** BOLD (Nasdaq Global Select Market)

**Business Focus:**
Boundless Bio is a clinical-stage biotechnology company specializing in the development of innovative therapeutic approaches for cancer treatment. The company is dedicated to addressing the unmet medical needs of patients with oncogene amplified tumors by targeting **extrachromosomal DNA (ecDNA)**—a key factor in oncogene amplification present in 14-17% of cancer patients.

### Key Research Areas:
1. **ecDNA Biology:** The company leverages its proprietary **Spyglass platform** to identify and develop drugs that can target ecDNA, which plays a crucial role in oncogene amplification in cancer cells.
2. **Therapeutics Development:** Their primary product, **BBI-355**, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) aimed at treating oncogene amplified cancers. 
3. **Clinical Trials:** Boundless Bio is conducting the **POTENTIATE trial**, which is a Phase 1/2 clinical trial evaluating the safety and efficacy of BBI-355 in patients with oncogene amplified tumors.

### Business Model:
- Boundless Bio operates primarily as a research and development-focused entity, with no products currently available for commercial sale. The company is in the early stages of developing its therapies and diagnostics targeting specific cancer characteristics, which include:
  - **ecDNA Diagnostic (ECHO):** Used for patient selection and monitoring the presence of ecDNA in tumors.
  
### Financials:
- **Employees:** 64 full-time employees as of March 21, 2025, with 20 holding M.D. or Ph.D. degrees.
- **Revenue:** As of December 31, 2024, Boundless Bio reported **$0** in revenue, as it has not yet commercialized any products.
- **Net Loss:** The company's net losses were **$65.4 million** for the year ended December 31, 2024, and **$49.4 million** for the year ended December 31, 2023. The accumulated deficit as of December 31, 2024, was **$201.5 million**.

### Customer Base:
- While specific customer numbers are not available since the company has not launched any commercial products, Boundless Bio targets oncologist practices and healthcare providers that treat patients with oncogene amplified cancers.

### Future Outlook:
The primary goal for Boundless Bio is to advance BBI-355 through clinical trials towards regulatory approval, while also identifying additional ecDTx candidates and exploring commercial partnerships to enhance its market position in oncology. The company aims to offer transformative therapies and diagnostics for cancer patients who are currently underserved by existing treatment options. 

---

This summary provides an overview of Boundless Bio, Inc., emphasizing its focus on cancer therapeutics targeting ecDNA, along with relevant financial and operational details.


Boundless Bio, Inc.

10-K / March 9, 2026

10-K / March 27, 2025

10-K / March 9, 2026